WO2012151577A3 - Techniques destinées à augmenter r1 dans des agents de contraste à nanoparticules pour l'irm - Google Patents

Techniques destinées à augmenter r1 dans des agents de contraste à nanoparticules pour l'irm Download PDF

Info

Publication number
WO2012151577A3
WO2012151577A3 PCT/US2012/036787 US2012036787W WO2012151577A3 WO 2012151577 A3 WO2012151577 A3 WO 2012151577A3 US 2012036787 W US2012036787 W US 2012036787W WO 2012151577 A3 WO2012151577 A3 WO 2012151577A3
Authority
WO
WIPO (PCT)
Prior art keywords
mri
techniques
increase
contrast agents
nanoparticle contrast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/036787
Other languages
English (en)
Other versions
WO2012151577A2 (fr
Inventor
Kevin Bennett
Maria Veronica CLAVIJO-JORDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skysong Innovations LLC
Original Assignee
Arizona Science and Technology Enterprises LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Science and Technology Enterprises LLC filed Critical Arizona Science and Technology Enterprises LLC
Publication of WO2012151577A2 publication Critical patent/WO2012151577A2/fr
Anticipated expiration legal-status Critical
Publication of WO2012151577A3 publication Critical patent/WO2012151577A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La présente invention concerne une nouvelle nanoparticule apoferritine et des utilisations de ladite nanoparticule dans l'imagerie.
PCT/US2012/036787 2011-05-05 2012-05-07 Techniques destinées à augmenter r1 dans des agents de contraste à nanoparticules pour l'irm Ceased WO2012151577A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482758P 2011-05-05 2011-05-05
US61/482,758 2011-05-05

Publications (2)

Publication Number Publication Date
WO2012151577A2 WO2012151577A2 (fr) 2012-11-08
WO2012151577A3 true WO2012151577A3 (fr) 2014-04-17

Family

ID=47108274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/036787 Ceased WO2012151577A2 (fr) 2011-05-05 2012-05-07 Techniques destinées à augmenter r1 dans des agents de contraste à nanoparticules pour l'irm

Country Status (1)

Country Link
WO (1) WO2012151577A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ308442B6 (cs) * 2012-12-21 2020-08-26 Mendelova Univerzita V Brně Způsob přípravy nanočástic apoferritinu s uzavřeným protinádorovým léčivem
AU2019337699B2 (en) * 2018-09-13 2025-05-08 The Regents Of The University Of Michigan Small highly uniform nanomedicine compositions for therapeutic, imaging and theranostic applications
CN109576310B (zh) * 2018-12-11 2021-08-10 大连理工大学 一种生物氧化制备石墨烯铁氧化物复合材料的方法
US20250376503A2 (en) * 2020-10-06 2025-12-11 The Board Of Trustees Of The Leland Stanford Junior University Protein double-shell nanostructures and their use
WO2024199059A1 (fr) * 2023-03-31 2024-10-03 四川瀛瑞医药科技有限公司 Utilisation d'injection de suspension de nanocarbone-fer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
US20080014621A1 (en) * 2006-07-13 2008-01-17 National Institute Of Aerospace Associates Fabrication of metal nanoshells
US20090324494A1 (en) * 2006-02-24 2009-12-31 Atgen Co., Ltd Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
US20110014129A1 (en) * 2009-04-03 2011-01-20 Gary Zabow Magnetic microstructures for magnetic resonance imaging

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
US20090324494A1 (en) * 2006-02-24 2009-12-31 Atgen Co., Ltd Magnetic nano-composite for contrast agent, intelligent contrast agent, drug delivery agent for simultaneous diagnosis and treatment, and separation agent for target substance
US20080014621A1 (en) * 2006-07-13 2008-01-17 National Institute Of Aerospace Associates Fabrication of metal nanoshells
US20110014129A1 (en) * 2009-04-03 2011-01-20 Gary Zabow Magnetic microstructures for magnetic resonance imaging

Also Published As

Publication number Publication date
WO2012151577A2 (fr) 2012-11-08

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
IL272035A (en) Anti IL–36R antibodies
IL231215A0 (en) Modification of peg to nanoparticles of h-phosphonates
IL231846A0 (en) Antibodies against c-met and their uses
IL235261A0 (en) Antibodies against claudin 18.2 for use in the diagnosis of cancer
EP2756094A4 (fr) Anticorps anti-b7-h4 et leurs utilisations
SG11201403953QA (en) SOLUBLE IMMUNOREACTIVE <i>TREPONEMA PALLIDUM</i> TPN47 ANTIGENS
WO2012151577A3 (fr) Techniques destinées à augmenter r1 dans des agents de contraste à nanoparticules pour l'irm
LT2771068T (lt) Magnetinis difuzinis pleistras
Kinsley et al. Maternal Mentality
Milićević Marsov krater Milanković
GB201005958D0 (en) Mr.sasan yadrandji aghdam
AU2012901455A0 (en) Magnetic engine
GB201109702D0 (en) Magnetometry
GB201212163D0 (en) In-vehicle seating
GB201116301D0 (en) In-vehicle seating
AU2011905352A0 (en) Imaging agents
AU2011901009A0 (en) jmd s.p. 300.
GB201121054D0 (en) The National Car Buyers Database
GB201110610D0 (en) Magnetic engine
AU2011903205A0 (en) Haptoglobin Variant For Diagnosis In Pregnancy Induced Hypertensive Disorders
PL394908A1 (pl) Nanonapelniacze hybrydowe oraz sposób ich otrzymywania metoda bifunkcjonalizacji
AU2011012V (en) LEO 4363 Aloe hybrid
GB201111686D0 (en) In vehicle seating
PH32011000805S1 (en) Flask edt es 50

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12779341

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12779341

Country of ref document: EP

Kind code of ref document: A2